NCCN Lists Ropeginterferon Alfa-2B As Preferred First-Line Cytoreductive Therapy for PV
The National Comprehensive Cancer Network recommends ropeginterferon alfa-2b as first-line cytoreductive therapy for polycythemia vera.
Source: onclive.com
El Chaer News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from El Chaer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In El Chaer Today - Breaking & Trending Today
RSV Vaccines See a Pricey Leap Forward in Disease Prevention
Older adults without a Part D plan face costs ranging from $180 to $295 per shot.
Source: pharmacytimes.com
Takeda UK Ltd: NICE recommends LIVTENCITY? (maribavir) for the treatment of adults with post-transplant cytomegalovirus (CMV) refractory (with or without resistance) to prior therapies
Takeda UK Ltd. is pleased to announce that NICE has recommended the use of LIVTENCITY? (maribavir) as a twice daily oral treatment for adult patients with post-transplant cytomegalovirus (CMV)
Source: finanznachrichten.de
Health Canada approves Takeda's LIVTENCITY™ (maribavir) the First and Only Treatment for Adults with Post-Transplant Cytomegalovirus (CMV) infection
TORONTO, Sept. 20, 2022 /CNW/ - Takeda Canada Inc. is pleased to announce that Health Canada has authorized LIVTENCITY™ for the treatment of adults with post-transplant cytomegalovirus ... | September 20, 2022
Source: marketscreener.com